HTG Molecular Diagnostics, Inc. (HTGM)
| Market Cap | 41.81M |
| Revenue (ttm) | 7.87M |
| Net Income (ttm) | -17.17M |
| Shares Out | 6.69M |
| EPS (ttm) | -3.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,994 |
| Open | 5.69 |
| Previous Close | 5.65 |
| Day's Range | 5.66 - 5.85 |
| 52-Week Range | 3.50 - 7.95 |
| Beta | 1.48 |
| Analysts | Buy |
| Price Target | 9.75 (+70.8%) |
| Est. Earnings Date | Nov 9, 2021 |
About HTGM
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq D...
Financial Performance
In 2020, HTGM's revenue was $8.55 million, a decrease of -55.48% compared to the previous year's $19.20 million. Losses were -$20.87 million, 8.15% more than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for HTGM stock is "Buy." The 12-month stock price forecast is 9.75, which is an increase of 70.75% from the latest price.
News
HTG Expands Therapeutics Team
Veteran Drug Developer Stephen Barat, Ph.D. Joins to Head Company's Therapeutics Division Veteran Drug Developer Stephen Barat, Ph.D. Joins to Head Company's Therapeutics Division
HTG Molecular Diagnostics to Present at H.C. Wainwright's 23rd Annual Global Investment Conference
TUCSON, Ariz., Sept. 08, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that compan...
HTG Molecular Diagnostics Reports Second Quarter 2021 Results
Call scheduled for today, August 12, at 4:30pm ET Call scheduled for today, August 12, at 4:30pm ET
HTG's New HTG Transcriptome Panel Launched with Commercial Availability in the U.S. and Europe
HTG Transcriptome Panel designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology
HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TUCSON, Ariz., July 23, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that, on Jul...
HTG Receives First Order For HTG Transcriptome Panel, Enters Two European EAP Agreements
HTG Molecular Diagnostics Inc (NASDAQ: HTGM) has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) col...
HTG EdgeSeq Technology Highlighted in Several Posters Being Presented at the American Society of Clinical Oncology 20...
TUCSON, Ariz., May 24, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that its HTG ...
HTG Molecular Diagnostics Reports First Quarter 2021 Results and Provides a Corporate Update
Call scheduled for today, May 13, at 4:30 pm ET Call scheduled for today, May 13, at 4:30 pm ET
HTG Molecular Diagnostics to Announce Q1 2021 Financial Results and Host Conference Call on Thursday, May 13
TUCSON, Ariz., May 04, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report...
HTG Molecular Diagnostics Reports Preliminary First Quarter 2021 Financial Results
TUCSON, Ariz., April 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain prel...
HTG Molecular Diagnostics Reports Full Year 2020 Results
Call scheduled for today, March 25, at 4:30pm ET Call scheduled for today, March 25, at 4:30pm ET
Earnings Preview: HTG Molecular Diagnostics, Inc. (HTGM) Q4 Earnings Expected to Decline
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HTG Molecular Diagnostics to Announce Year End 2020 Financial Results and Host Conference Call on Thursday, March 25
TUCSON, Ariz., March 16, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will repo...
3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a $1.8 billion deal on Monday, the same day Veracyte Inc (NASDAQ: VCYT) announced it completed the acquisition of Deciph...
HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG E...
TUCSON, Ariz., Feb. 26, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has compl...
HTG Announces Board of Directors Transition
Timothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director Timothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director
HTG Expands Patent Portfolio with New Canadian Patent for its Nuclease Protection Methods for Detection of Nucleotide...
TUCSON, Ariz., Dec. 30, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has ...
HTG Announces First Collaborator in Early Access Program for its Prototype Whole Transcriptome Panel
TUCSON, Ariz., Dec. 18, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has ...
HTG Announces an Early Access Program for its Prototype Whole Transcriptome Panel
TUCSON, Ariz., Dec. 08, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has ...
HTG Announces One-for-Fifteen Reverse Stock Split
TUCSON, Ariz., Nov. 23, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that as a result o...
HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q3 2020 Results - Earnings Call Transcript
HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q3 2020 Results - Earnings Call Transcript
HTG Molecular Diagnostics: Q3 Earnings Insights
Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) decreased 3.2% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 53.33% year over year to ($0.07)...
HTG Molecular Diagnostics Reports Third Quarter 2020 Results
Call scheduled for today, November 10, at 4:30pm ET Call scheduled for today, November 10, at 4:30pm ET
HTG Demonstrates Technical Feasibility for a Whole Transcriptome Panel Using HTG EdgeSeq Technology
TUCSON, Ariz., Nov. 02, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the completi...
HTG Molecular Diagnostics to Announce Third Quarter 2020 Financial Results and Host Conference Call on Tuesday, Novem...
TUCSON, Ariz., Oct. 30, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will repor...